Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- RCT of CBD for Anxiety in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of RCT of CBD for Anxiety in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04482244).
- RCT-PASIndependent statistical analysis of Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05013749).
- RCTTMIndependent statistical analysis of Clinical Trial Tobacco Marijuana: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02277665).
- RDEBIndependent statistical analysis of A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- RDMEACCS100Independent statistical analysis of Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01677195).
- RDOcularUSIndependent statistical analysis of Use of Ocular Point of Care Ultrasound in Diagnosing Retinal Detachment in the Emergency Department: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- RDRIndependent statistical analysis of tDCS Effects on Resisting Smoking: Dose Ranging Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02624284).
- RDVCGHIndependent statistical analysis of Racial Differences in Vagal Control of Glucose Homeostasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02365285).
- RE-CHUTIndependent statistical analysis of Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed): primary endpoint results, effect estimate with confidence interval, sample-size…
- RE-COVER IComplete statistical analysis of RE-COVER I, the randomized phase 3 trial comparing dabigatran 150 mg with warfarin for 6 months in patients with acute symptomatic venous thromboembolism, including non-inferiority methodology, time-to-event analyses,…
- RE-COVER IIIndependent statistical analysis of Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE): primary endpoint results, effect estimate…
- RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism: Complete Statistical AnalysisIndependent statistical analysis of RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RE-DAXIndependent statistical analysis of Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436: Complete Statistical AnalysisIndependent statistical analysis of Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534897).
- Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients: Complete Statistical AnalysisIndependent statistical analysis of Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00675103).
- Re-expression of ER in Triple Negative Breast Cancers: Complete Statistical AnalysisIndependent statistical analysis of Re-expression of ER in Triple Negative Breast Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01194908).
- RE-IORT01Independent statistical analysis of Intraoperative Radiotherapy After Local Recurrence in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02386371).
- Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size…
- RE-MEDYA detailed statistical analysis of the randomized phase 3 RE-MEDY trial comparing dabigatran with warfarin for secondary prevention of venous thromboembolism, including time-to-event methodology, non-inferiority analysis, bleeding outcomes, and statistical interpretation.
- RE-PACTIndependent statistical analysis of Respiratory Exacerbation Plans for Action and Care Transitions for Children With Severe CP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- REACH 5Independent statistical analysis of Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant: primary endpoint results, effect estimate with confidence…
- REACH IIIIndependent statistical analysis of Researching Emotions And Cardiac Health: Phase III: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03220204).
- REACH Implicit Bias Training Project: Complete Statistical AnalysisIndependent statistical analysis of REACH Implicit Bias Training Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03415308).
- Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: Complete Statistical AnalysisIndependent statistical analysis of Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: primary endpoint results, effect estimate with confidence interval, sample-size…
- REACTComplete statistical analysis of the REACT phase 3 trial of two years of adjuvant celecoxib versus placebo in primary breast cancer, including trial design, disease-free survival, overall survival, statistical methodology, and interpretation.
- REACTIndependent statistical analysis of Safety and Efficacy of Ranibizumab for Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01982435).
- Reactions to Warnings on Hookah Ads: Complete Statistical AnalysisIndependent statistical analysis of Reactions to Warnings on Hookah Ads: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03723616).
- READERIndependent statistical analysis of A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image: Complete Statistical AnalysisIndependent statistical analysis of Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- READYComplete statistical analysis of the READY phase 3 trial of docetaxel plus dasatinib versus docetaxel plus placebo in castration-resistant prostate cancer, including trial design, overall survival, secondary endpoints, statistical methodology, safety, and…
- READY-1Independent statistical analysis of Treatment of Moderate to Severe Glabellar Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04249583).
- READY-2Independent statistical analysis of Treatment of Moderate to Severe Lateral Canthal Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04249687).
- READY-4Independent statistical analysis of Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- REALIndependent statistical analysis of A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01075763).
- REAL 2Independent statistical analysis of A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth…
- Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study: Complete Statistical AnalysisIndependent statistical analysis of Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity: Complete Statistical AnalysisIndependent statistical analysis of Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity: primary endpoint results, effect estimate with confidence interval,…
- Real World Glycemic Effectiveness of Linagliptin: Complete Statistical AnalysisIndependent statistical analysis of Real World Glycemic Effectiveness of Linagliptin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03338803).
- Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO: Complete Statistical AnalysisIndependent statistical analysis of Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients – A Multi Center Chart Review: Complete Statistical AnalysisIndependent statistical analysis of Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review:…
- REAL-ICUIndependent statistical analysis of Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program: Complete Statistical AnalysisIndependent statistical analysis of Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01662336).
- Real-PD Trial: Development of Clinical Prognostic Models for Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02474329).
- Real-time fMRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD: Complete Statistical AnalysisIndependent statistical analysis of Real-time fMRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Real-Time fMRI Feedback Effects on Pain Perception: Complete Statistical AnalysisIndependent statistical analysis of Real-Time fMRI Feedback Effects on Pain Perception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01588197).
- Real-time Location System Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of Real-time Location System Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03988751).
- REAL-TIMI 63BIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor: Complete Statistical AnalysisIndependent statistical analysis of Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05361655).
- Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China: Complete Statistical AnalysisIndependent statistical analysis of Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02668640).